Citations

Clear

421 citation(s) found for "Short, C".

Short-Term Outcomes of Endoscopic Ultrasound-Guided Pancreatic Cyst Ablation: A Systematic Review and Meta-Analysis 
Qady, Ahmed Al , Nayar, Kapil Dev, Emran, Joseph, Beirat, Amir , Menakuru, Sasmith, Echols, Dan J., Ji, Baoan , Wang, Zhen , Bi, Yan , Nayar, Kapil Dev, Harris, Dana M. , DeWitt, John M. , Stancampiano, Fernando F.

Mayo Clinic

No container title available | April 2, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4165948/v1 Get It

Abstract Background Pancreatic cysts (PC) are increasingly detected through abdominal imaging, prompting exploration of alternatives such as endoscopic ultrasound-guided pancreatic cyst ablation (EUS-PCA) due to the risks and costs associated with surgery. This study conducts a systematic review and meta-analysis of EUS-PCA's short-term efficacy and complications for PC management. Methods A systematic review and meta-analysis were carried out on PubMed, Ovid, Cochrane, and TRIP electronic databases. The primary outcome was cyst resolution (partial and complete) and persistence on imaging 12 months after ablation. The secondary outcome was procedure-related adverse events. Results Eight studies were eligible for analysis. Complete cyst resolution on imaging 12 months after EUS ablation was 50% [95% CI 36, 63, I2 = 85.31%]. Partial cyst resolution was 27% [95% CI 15, 41, I2 = 87.07%], and cyst persistence was 17% [95% CI 11, 24, I2 = 62.11%]. The rate of complete resolution varied depending on the treatment agent (for ethanol 29% [95% CI 10, 53], lauromacrogol 51% [95% Cl 36, 67], ethanol and paclitaxel 63% [95% CI 48, 76], paclitaxel and gemcitabine 67% [95% CI 45, 83], ethanol, paclitaxel and gemcitabine 61% [95% CI 39, 80]). Post-procedure adverse events included abdominal pain in 4% [95% CI 0, 11], pancreatitis in 3% [95% CI 1, 5], and fever in 1% [95% CI 0, 3] of all patients. Conclusion The treatment of pancreatic cysts with EUS ablation results in acceptable levels of complete resolution, and low incidence of severe adverse events. The effectiveness of this treatment is further enhanced when chemoablative agents are employed.
Management of undifferentiated embryonal sarcoma of the liver: A Pediatric Surgical Oncology Research Collaborative study
Kastenberg, Zachary J. , Short, Scott S. , Riehle, Kimberly J. , Lautz, Timothy B. , Ott, Katherine C. , Murphy, Andrew J. , Mansfield, Sara A. , Hallis, Brian, Murphy, Joseph, Roach, Jonathan P. , Polites, Stephanie F. , Beckhorn, Catherine B , Fialkowski, Elizabeth , Seemann, Natashia M. , Bütter, Andreana , Rich, Barrie S. , Glick, Richard D. , Bondoc, Alex, Ofori-Atta, Blessing , Zamora, Abigail K., Vasudevan, Sanjeev A. , Rinehardt, Hannah , Lapidus‐Krol, Eveline , Meyers, Rebecka L. , Tiao, Greg , Dasgupta, Roshni , Baertschiger, Reto M. , Lautz, Timothy , Murphy, Andrew J , Beckhorn, Catherine , Tracy, Elisabeth T , Fialkowski, Elizabeth A , Seemann, Natashia M , Malek, Marcus M , Baertschiger, Reto , Kastenberg, Zachary J , Dasgupta, Roshni , Utria, Alan Fremder , Lal, Dave R. , Tracy, Elisabeth T. , Bondoc, Alexander , Presson, Angela P. , Chen, Stephanie , Kim, Eugene S. , Malek, Marcus M. , Putra, Juan , Superina, Riccardo Antonio , Langham, Max Raymond

Mayo Clinic

Pediatric Blood & Cancer | April 1, 2024 | Volume: 71 | Issue: 6 | Pages: No page available

10.1002/pbc.30975 | PMID 38556718 Get It

AbstractBackgroundUndifferentiated embryonal sarcoma of the liver (UESL) is a rare tumor for which there are few evidence‐based guidelines. The aim of this study was to define current management strategies and outcomes for these patients using a multi‐institutional dataset curated by the Pediatric Surgical Oncology Research Collaborative.MethodsData were collected retrospectively for patients with UESL treated across 17 children's hospitals in North America from 1989 to 2019. Factors analyzed included patient and tumor characteristics, PRETEXT group, operative details, and neoadjuvant/adjuvant regimens. Event‐free and overall survival (EFS, OS) were the primary and secondary outcomes, respectively.ResultsSeventy‐eight patients were identified with a median age of 9.9 years [interquartile range [IQR): 7–12]. Twenty‐seven patients underwent resection at diagnosis, and 47 patients underwent delayed resection, including eight liver transplants. Neoadjuvant chemotherapy led to a median change in maximum tumor diameter of 1.6 cm [IQR: 0.0–4.4] and greater than 90% tumor necrosis in 79% of the patients undergoing delayed resection. R0 resections were accomplished in 63 patients (81%). Univariate analysis found that metastatic disease impacted OS, and completeness of resection impacted both EFS and OS, while multivariate analysis revealed that R0 resection was associated with decreased expected hazards of experiencing an event [hazard ratio (HR): 0.14, 95% confidence interval (CI): 0.04–0.6]. At a median follow‐up of 4 years [IQR: 2–8], the EFS was 70.0% [95% CI: 60%–82%] and OS was 83% [95% CI: 75%–93%].ConclusionComplete resection is associated with improved survival for patients with UESL. Neoadjuvant chemotherapy causes minimal radiographic response, but significant tumor necrosis.
The Role of Radiotherapy in the Short- and Long-Term Survival for Craniopharyngiomas: A National Cancer Database Analysis
Alexander, Amiya, Kerezoudis, Panagiotis , Peris‐Celda, Maria , Alexander, A. Yohan, Agosti, Edoardo , Michalopoulos, Giorgos D. , Daniels, David J.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 21, 2024 | Volume: 85 | Issue: S 01 | Pages: S1-S398

10.1055/s-0044-1779976 Get It

Impact of ATS Resident Boot Camp on Faculty and Fellows who Teach
Bateman, Marjorie , Maximous, S. , Nelson, Darlene R. , Lee, May M. , Drake, Matthew G. , Short, Briana, Quaney, Rachel, Soffler, Morgan , Matta, Maroun, Drake, Matthew G

Mayo Clinic

ATS Scholar | February 2, 2024 | Volume: 5 | Issue: 2 | Pages: 247-253

10.34197/ats-scholar.2023-0105br | PMID 38957496 Get It

P433 Short-term outcomes of surgical treatment in primary ileocecal Crohn’s disease patients. Results of Crohn’s(urg) study, multicenter, retrospective, comparative analysis between indications for luminal and complicated phenotype
Bislenghi, Gabriele , D’Hoore, André , Juachon, Patrizia, Harsløf, Sanne , Gomez, Joanne Michelle D. , Merchea, Amit , Shacker, A, Gallostra, M Marti, Maruyana, B Yuki, Garoufalia, Zoe , Zhihui, C, Rrupa, Djana , Haanappel, Anouck , Giorgi, Lorenzo , Avellaneda, Nicolás , Pellino, Gianluca , Maroli, Annalisa , Tottrup, A, Colpaert, J, Giorgi, L, Overstraeten, Anthony de Buck van , Olivera, Pablo Andres , Gomez, J, Holubar, Stefan D. , Lincango-Naranjo, Eddy , Steele, Scott R. , Gallostra, M Marti, Kraft, Miquel , Kotze, Paulo Gustavo , Wexner, Steven D. , Zhihui, C, Hahnloser, Dieter , Buskens, Christianne Johanna , Warusavitarne, Janindra H. , Williams, K, Christensen, Peter , Spinelli, Antonino

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i881-i883

10.1093/ecco-jcc/jjad212.0563 Get It

Abstract Background Recent evidence challenges the current standard of offering surgery to patients with ileocecal Crohn’s disease only when they present complications of the disease. Methods A retrospective, multicenter comparative analysis was performed including patients operated for primary ileocecal CD at 12 referral centers. Patients were divided in 2 groups, according to indication of surgery for inflammatory (ICD) or complicated (CCD) phenotype. Short-term results were compared. Patients operated on for primary isolated ileocaecal CD (last 50 cm of the terminal ileum and cecum), either for predominantly inflammatory phenotype or for complications of the disease (stricturing or fistulizing pattern), between January 2012 - December 2021 were considered eligible to participate in this study. Patients with previous abdominal procedures for CD, and patients who had activity of the disease in other intestinal segments other than the ileocaecal region at the time of surgery, were excluded from the study. Results 2013 patients were included, 291 (14.5%) in the ICD group. No differences were found between groups in time from diagnosis to surgery or in the levels of exposure to biologic drugs before indication of surgery. CCD patients had higher rates of low BMI, anemia (40.9 vs. 27%, p: < 0.001), and low albumin (11.3 vs. 2.6%, p: < 0.001). CCD patients had longer operations, lower rates of laparoscopic approach (84.3 vs. 93.1%, p: 0.001), and higher conversion rates (9.3 vs. 1.9%, p: < 0.001). CCD had longer hospital stay and higher postoperative complication rates (26.1 vs. 21.3%, p: 0.083). Anastomotic leakage and reoperations were also more frequent in this group. More patients in the CCD group required an extended bowel resection (14.1 vs. 8.3%, p: 0.017). In multivariate analysis, CCD was associated with prolonged surgeries (OR: 3.44, p: 0.001) and requirements of multiple intraoperative procedures (OR: 8.39, p: 0.030). Conclusion Indication of surgery in patients who present an inflammatory phenotype of CD was associated with better outcomes when compared to patients operated on for complications of the disease, without a difference between groups in time from diagnosis to surgery.
Improved Outcomes Associated With Teduglutide Use in Patients With Both Short Bowel Syndrome and Crohn’s Disease
Siu, Rex K. , Karime, Christian , Hashash, Jana G. , Kinnucan, Jami , Picco, Michael F., Farraye, Francis A. , Farraye, Francis A , Hashash, Jana G

Mayo Clinic

Crohn's & Colitis 360 | January 23, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.1093/crocol/otae007 | PMID 38352117 Get It

Abstract Introduction Crohn’s disease (CD) with short bowel syndrome (SBS) can present as chronic intestinal failure (CIF) often requiring nutritional support. Teduglutide is a treatment option for these patients. We investigated clinical outcomes of CD-CIF patients with SBS treated with teduglutide. Methods Adults with CD-CIF and SBS who received teduglutide were identified at a tertiary care academic center between 2012 and 2023. Data was collected retrospectively. Primary outcome measured was reduction in parenteral support (PS) by ≥20% volume, with PS defined as utilization of parenteral nutrition (PN) or intravenous fluids (IVF). Several secondary outcomes included immunosuppressive medication changes, subjective symptom improvement, and stool output. Results We identified 32 patients with CD-CIF and SBS receiving teduglutide. Comparing clinical outcomes before and after teduglutide, 26 of 32 patients achieved the primary outcome of ≥20% PS reduction. A decrease was seen in patients requiring PN + IVF, with corresponding increases in patients requiring PN only and IVF only. Among all 3 groups, a total of 23 patients received PN prior to teduglutide, which decreased to 14 following teduglutide. Weekly PN volume reduced from 7.00 to 3.55 L and weekly frequency decreased from 7.00 to 3.00 instances (P < .01). Reductions in weekly volume and frequency were observed among all patients receiving IVF support (25 vs 15). Secondary outcomes showed improvement in patient reported subjective symptoms (84.4%), stool output (90.6%), patients meeting criteria for diarrhea/high ostomy output (27 vs 14), and use of unique antidiarrheal medications (3.0 vs 2.0). Conclusions This retrospective case series demonstrated improved clinical outcomes in patients with CD-CIF and SBS treated with teduglutide resulting in decreased PS requirements, antidiarrheal medications requirement, and stool output without significant effects on immunosuppressive therapy.
Functional Return‐to‐Sport Testing Demonstrates Inconsistency in Predicting Short‐Term Outcomes Following Anterior Cruciate Ligament Reconstruction: A Systematic Review
Gill, Vikram S. , Tummala, Sailesh V. , Sullivan, Georgia , Han, Will, Haglin, Jack M. , Marks, Lisa , Tokish, John M. , Marks, Lisa A , Tummala, Sailesh V

Mayo Clinic

Arthroscopy | January 11, 2024 | Volume: 40 | Issue: 7 | Pages: 2135

10.1016/j.arthro.2023.12.032 | PMID 38216071 Get It

Purpose To systematically review the relationship between functional testing at the time of return to sport (RTS) and short‐term outcomes, such as second anterior cruciate ligament (ACL) tear and return to a preinjury level of sport, among athletes who underwent anterior cruciate ligament reconstruction (ACLR). Methods A systematic literature search was performed in MEDLINE, EMBASE, Scopus, and Web of Science to identify studies examining athletes who underwent functional RTS testing and were followed for at least 12 months following ACLR. Studies were screened by 2 reviewers. A standardized template was used to extract information regarding study characteristics, ACLR information, functional test results, and risk factors associated with retear or reduced RTS. Results Of the 937 studies identified, 22 met the inclusion criteria. The average time between ACLR and RTS testing was 8.5 months. Single leg hop for distance performance had no association with retear risk in any study and no association with RTS rates in most studies. Quadriceps strength had conflicting results in relation to retear risk, whereas it had no relationship with RTS rates. Rates of reinjury and RTS were similar between patients who passed and did not pass combined hop and strength batteries. Asymmetric knee extension and hip moments, along with increased knee valgus and knee flexion angles, demonstrated increased risk of retear. Conclusions Individual hop and strength tests that are often used in RTS protocols following ACLR may have limited and inconsistent value in predicting ACL reinjury and reduced RTS when used in isolation. Combined hop and strength test batteries also demonstrate low sensitivity and negative predictive value, highlighting conflicting evidence to suggest RTS testing algorithm superiority. Level of Evidence Level IV, systematic review of Level I‐IV studies.
PF484 MARKERS ASSOCIATED WITH SHORT SURVIVAL IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
Ruan, Gordon , Abeykoon, Jithma P. , Zanwar, Saurabh , Ansell, Stephen M. , Reeder, Craig B. , Lacy, Martha Q. , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Gertz, Morie A. , Ailawadhi, Sikander , Dispenzieri, Angela , Dingli, David , Go, Ronald S. , Leung, Nelson , Buadi, Francis K. , Gonsalves, Wilson I. , Rajkumar, S. Vincent

Mayo Clinic

HemaSphere | December 31, 2023 | Volume: 3 | Issue: S1 | Pages: 194

10.1002/j.2572-9241.2019.tb00083.x Get It

Background:Waldenström Macroglobulinemia (WM) is a rare, indolent B‐cell lymphoplasmacytic malignancy. Patient outcomes are highly heterogeneous, with a proportion of patients surviving less than 5 years (short survivors) and another proportion that survive longer than 10 years. The laboratory parameters in the currently used International Prognostic Scoring System for WM (IPSSWM) include hemoglobin, serum IgM, platelet count, and serum β2‐microglobulin.Aims:We aim to identify unique patient characteristics and prognostic features associated with short survival in WM.Methods:The medical records of patients with active WM that were diagnosed at Mayo Clinic Rochester, Arizona, and Florida between January 1st, 1996 and December 31st, 2013 were reviewed. The patients with smoldering WM were excluded. Cohorts of patients who either survived ≤ 5 years (Short Survival Group) or those with an overall survival (OS) ≥ 10 years (Long Survival Group) from the diagnosis of active disease were compared. Survivors with a follow‐up of ≤ 5 years were not included in the analyses. Two‐sided Wilcoxon rank sum test and Chi square/Fisher's exact test were used to compare the continuous and categorical variables, respectively. The variables that were statistically significant on univariate analysis (P < 0.05) were included in a multivariate logisitic regression analysis.Results:Of 893 consecutively seen WM patients (median follow‐up of 9 years [95% CI 8.4–9.7]), we identified 387 patients who could be categorized into either the Short Survival Group (n = 171 patients, 44%) or the Long Survival Group (n = 216, 56%). The Short Survival Group had a median OS of 2.4 years (2.1–2.8) and median age at diagnosis of 73 years (42–93), while the Long Survival Group (n = 216, 56%) had a median OS of 18.9 years (16‐NR) and median age at diagnosis of 62 years (31–85). The baseline characteristics and significant findings between the two groups are listed in the Table. Parameters significant on univariate analysis included age >65 years, albumin < 3.5 g/dL, β2‐microglobulin >3 μg/ml, and LDH > upper limit of normal (ULN). On multivariate analysis, albumin <3.5 g/dL and LDH > ULN were independently associated with short survival. Among the Long Survivors, 60 (28%) patients survived 15 years or more.Summary/Conclusion:Lactate dehydrogenase above the ULN and serum albumin <3.5 g/dL are independent biomarkers of short survival in WM. The MYD88 L265P status and the size of serum IgM are not prognostic in WM. Our data suggest the need for simplification of the current staging system with the use of widely available markers: serum albumin and lactate dehydrogenase.image
Malignant glomus tumor arising in association with a fumarate hydratase‐deficient leiomyoma: An unusual collision tumor
Short, Emma , Logan, Suzanna , Thangaiah, Judith Jebastin, Folpe, Andrew L. , Short, Emma L , Logan, Suzanna J

Mayo Clinic

Journal of Cutaneous Pathology | December 23, 2023 | Volume: 51 | Issue: 4 | Pages: 272-275

10.1111/cup.14585 | PMID 38140939 Get It

AbstractCollision tumors, defined as “two independent neoplasms that occur in close proximity to one another but maintain distinct boundaries,” are quite rare. We report an exceptional collision tumor composed of a genetically confirmed malignant glomus tumor and a fumarate hydratase (FH)‐deficient leiomyoma, presenting as a subcutaneous thigh mass in a 38‐year‐old male who was known to have hereditary leiomyomatosis and renal cell carcinoma syndrome. Microscopic examination identified a biphasic subcutaneous mass comprising sheets and nodules of glomus cells, with nuclear atypia and mitotic activity, and fascicles of mitotically inactive smooth muscle with variably pleomorphic nuclei and intracytoplasmic eosinophilic inclusions, features of FH‐deficient leiomyoma. Immunohistochemistry demonstrated loss of FH and robust 2‐succinocysteine expression in the smooth muscle, with a normal (FH‐retained) expression pattern in the glomus tumor. Next‐generation sequencing, performed on the glomus tumor component, identified CARMN::NOTCH2 fusion, characteristic of malignant glomus tumors. Awareness of the distinctive morphologic, immunohistochemical, and molecular genetic features of glomus tumors and FH‐deficient leiomyomas is important for correct clinical management of patients with exceptional collision tumors of this type.
Quantitative Gait Analysis Techniques Detect Change Congruent with Patient Perceptions after Corticosteroid Treatment: A Pilot Study of Short-Term Change in Progressive MS (P04.105)
Yin, Siyang, Arumugan, Easwara, He, Jiping , Wingerchuk, Dean M. , Cortez, Melissa , Yin, Siyang, Zhang, Siwei

Mayo Clinic

Neurology | December 7, 2023 | Volume: 80 | Issue: 7_supplement | Pages: No page available

10.1212/wnl.80.7_supplement.p04.105 Get It